Bertilimumab (CAT 213) (0.01-10 mg/kg) administered i.v. 30 min before i.po. injection of human eotaxin1 (1 μg) causes a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. Bertilimumab also significantly inhibits neutrophil and mononuclear cell influx into the air pouch, which resulted in a dose-related inhibition of total cell influx[1].
| Animal Model: | Female BALB/c mice (17-21 g) injected human eotaxin1[1]. |
| Dosage: | 0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, 10 mg/kg |
| Administration: |
i.v; once |
| Result: | Caused a significant dose-dependent inhibition of eosinophil recruitment in IL-5-treated, ovalbumin-sensitized mice. |
